Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label pediatric subcutaneous anifrolumab study in systemic lupus erythematosus
MOH_2026-08-27_017014Phase 2Not yet recruiting
- Sponsor
- AstraZeneca
- Start
- Aug 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of anifrolumab in systemic lupus erythematosus (SLE) (2 cohorts), sponsored by AstraZeneca. Primary endpoints: Pharmacokinetics of subcutaneous anifrolumab, Pharmacodynamics of subcutaneous anifrolumab and 1 more. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
anifrolumab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on MOH_2026-08-27_017014.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2026-08-27_017014.